BCAB and CNTX Related Headlines

Go Back

May 18, 2026 06:45AM Context Therapeutics amends BioAtla license deal for CT-202 drug
May 18, 2026 06:45AM Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

BCAB and CNTX Related Press Releases

Go Back

May 18, 2026 06:45AM Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

BCAB and CNTX Related SEC Filings

Go Back